Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytidine and Creatine Augmentation in Bipolar Depression
NCT02625779Phase 2Withdrawn
- Sponsor
- Ewha Womans University Mokdong Hospital
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bipolar disorder (BD) comparing Valproate + Placebo, Valproate + Cytidine and Valproate + Creatine (3 arms). Primary endpoints: Change in symptoms of bipolar depression at 8 weeks and Change in depressive symptoms at 8 weeks. Planned start Mar 2016; status: withdrawn.
02
Drugs
Cytidinecreatine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT02625779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02625779.